Financial Performance and Outlook for Sanofi in Q2 2026

Sanofi SA, a French multinational pharmaceutical company listed on the NYSE and Euronext Paris, reported a strong second‑quarter performance for 2026. The company’s revenue and earnings metrics exceeded analyst expectations and prompted an upward revision of its 2026 guidance.

Revenue Growth

  • Quarterly sales increased by 17.8 % at constant exchange rates (CER1), reaching €11.60 billion.
  • At actual exchange rates, the company recorded a 16 % sales rise to €11.6 billion.
  • The increase was driven primarily by the launch of new pharmaceuticals: Ayvakit, ALTUVIIIO, and Sarclisa, which contributed €1.3 billion in sales—an +48.3 % gain.
  • Dupixent sales grew by 37.6 % to €5.2 billion, surpassing the €5 billion quarterly milestone for the first time.
  • Vaccines sales declined by 4.7 % to €1.1 billion, largely due to a high comparative base in influenza vaccine sales in the prior year.

Earnings

  • Business earnings per share (EPS) reached €2.09 for Q2, up 10 % above the consensus of €1.90.
  • The adjusted EPS of €2.09 compared with the prior period’s €1.59 represents a 31.4 % increase.
  • Research and Development (R&D) expenditures totaled €2.2 billion, marking a +17.9 % rise, reflecting investment in pipeline prioritizations.

Guidance Update

  • Sanofi has raised its 2026 revenue outlook to reflect a double‑digit growth trajectory, now targeting a ≈10 % increase at constant exchange rates.
  • The company’s updated guidance replaces the earlier expectation of a modest single‑digit rise.

Market Context

  • Sanofi’s market capitalization stands at €95.77 billion, with a 52‑week high of €91.15 (as of 2025‑10‑23) and a low of €71.73 (as of 2026‑05‑11).
  • The share price on 2026‑06‑11 closed at €76.59.
  • The price‑earnings ratio is 19.81.

Summary

Sanofi’s Q2 2026 results demonstrate robust sales momentum from its oncology, immunology, and cardiovascular product lines, particularly Dupixent and newly launched therapies. Strong earnings performance, coupled with a revised upward outlook, positions the company favorably for the remainder of the year.